A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT05861999
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Muscular Atrophy, Spinal
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Months - 24 Months
- Healthy Volunteers
- Not accepted
Interventions
- Risdiplam — DRUGParticipants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
Study Details
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children \<2 years of age genetically diagnosed with SMA.
Key Dates
- Start date
- Aug 14, 2024
- Status verified
- Jun 2026
- Primary completion
- Mar 31, 2028
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 28 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: RisdiplamParticipants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.
Primary Outcome Measure
Change from Baseline in the Raw Score of Bayley Scales of Infant and Toddler Development - Third Edition (BSID-III) Gross Motor Score at 72 Weeks of Risdiplam Treatment [ Time Frame: Baseline, Week 72 ]
Central Contacts
- Reference Study ID Number: BN44621 https://forpatients.roche.com/888-662-6728 (U.S. Only)
- Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72103 | - |
| Valley Children's Hospital | Madera | California | 93636 | - |
| Stanford Univ Medical Center | Palo Alto | California | 94304 | - |
| Children's Hospital of Colorado | Aurora | Colorado | 80045 | - |
| University of Florida Pediatrics | Gainesville | Florida | 32610 | - |
| Children's Healthcare of Atlanta Center for Advanced Pediatrics | Atlanta | Georgia | 30329-2309 | - |
| Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids | Michigan | 49503 | - |
| Children'S Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | - |
| Children's Hospital of the King's Daughter | Norfolk | Virginia | 23510 | - |
Find similar trials in Little Rock, AR
By research site
University of Arkansas for Medical Sciences· Little Rock, ARValley Children's Hospital· Madera, CAStanford Univ Medical Center· Palo Alto, CAChildren's Hospital of Colorado· Aurora, COUniversity of Florida Pediatrics· Gainesville, FLChildren's Healthcare of Atlanta Center for Advanced Pediatrics· Atlanta, GA
Related Studies
- A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their BabiesRecruiting · Biogen · Palo Alto, California
- A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular AtrophyPHASE2 · Recruiting · Hoffmann-La Roche · Chicago, Illinois
- A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyPHASE4 · Recruiting · Hoffmann-La Roche · Little Rock, Arkansas
- A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)PHASE1 · Recruiting · Biogen · Orange, California